Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-03-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celldonorcancertransplantprotocol
  Phrases that lowered it: bodytypebloodperiodpatients
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Minimum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 22 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.7% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports with a death: 19.8% (lowers risk) · Drug's FDA history
• Collaborators: 2 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 · started 2009 · scored riskier than 95% of active trials terminated
• Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab NCT00946023 · started 2009 · scored riskier than 98% of active trials terminated
• Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma NCT00856245 · started 2009 · scored riskier than 99% of active trials completed
• Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies NCT02483000 · started 2017 · scored riskier than 57% of active trials terminated
• Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma NCT01208896 · started 2011 · scored riskier than 55% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.